Benitec Biopharma Announces Updated Investor Webcast Information
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Leerink Partners Reiterates Outperform Rating on Benitec BioPharma (BNTC)
October 14, 2024 6:05 AM EDTLeerink Partners analyst Mani Foroohar reiterated an Outperform rating and $13.00 price target on Benitec BioPharma (NASDAQ: BNTC).
The analyst comments "This morning, BNTC announced additional data from its Phase 1b/2a trial evaluating BB-301 in oculopharyngeal muscular dystrophy (OPMD) at the 29th Annual Congress of... More



